10-Year Follow-Up: Pembrolizumab Outshines Ipilimumab in Advanced Melanoma

Long-term study shows pembrolizumab's superior efficacy over ipilimumab for advanced melanoma patients.

Oncology Pharmacy Team Apr 23, 2025

Durvalumab vs Cetuximab: No Advantage in Head and Neck Cancer Trial

Study finds durvalumab with radiotherapy no better than cetuximab for cisplatin-ineligible head and neck cancer

Oncology Pharmacy Team Apr 21, 2025

Study finds starting chemotherapy within 6 weeks after colorectal cancer surgery improves survival rates.

Oncology Pharmacy Team Apr 18, 2025

1 article

Sarcomas

Phase II trial reveals potential of ipilimumab and nivolumab combination in treating desmoid tumors

Oncology Pharmacy Team Nov 25, 2024